Summary:
Embrace the future of psoriasis care with the LATITUDE Psoriasis Studies. This program is evaluating an investigational oral treatment (pill) for adults with moderate to severe plaque psoriasis.
The investigational treatment works by helping to control inflammatory signals known to contribute to the buildup of plaque psoriasis. Participants will receive the investigational treatment, Otezla®* (an approved oral treatment for moderate to severe plaque psoriasis), or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures.
Participants originally assigned to placebo who still have active disease during the study will have the opportunity to switch to the investigational treatment. All study treatments will be given as oral pills.
*Otezla® is a registered trademark of Amgen Inc.
Qualified Participants Must:
We will need to ask you some prescreening questions to see if you would qualify for this study before we can schedule you for your first, paid, screening visit. We may ask these questions over the phone, or we can offer you an online questionnaire that may save you time.
If you do not qualify for this study, you might qualify for other psoriasis studies with us, or other clinical trials for other indications.
Qualified Participants will Receive:
Qualified participants who participate fully will receive at least $2,900 to a debit card. Plus, all of our patients receive free study-related care. Participants will receive the investigational treatment, Otezla®* (an approved oral treatment for moderate to severe plaque psoriasis), or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures.
Participants originally assigned to placebo who still have active disease during the study will have the opportunity to switch to the investigational treatment. All study treatments will be given as oral pills.
*Otezla® is a registered trademark of Amgen Inc.